New Atopic Dermatitis Yardstick provides practical guidance and management insights

January 4, 2018, American College of Allergy, Asthma, and Immunology

Patients with atopic dermatitis (AD) - also known as eczema - often face a tough, uphill battle for treatment. Symptoms include severe itching, scaly rashes, extreme dry skin and inflammation. Those who suffer from AD spend sleepless, itchy nights fearing they have nowhere to turn and their symptoms may never resolve. This creates therapeutic challenges for clinicians treating AD

According to a new yardstick published in Annals of Allergy, Asthma and Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI) for AD has changed a lot in the last few years. New treatments - including new drugs - are now available and can offer relief.

"The Atopic Dermatitis Yardstick was written by AD experts who are allergists and dermatologists because we want physicians who see patients with AD on a regular basis to know there are effective treatment options available," says allergist Mark Boguniewicz, MD, ACAAI Fellow and lead author of the yardstick. "In the yardstick, we cover the challenges and barriers to treatment success. We offer definitions of disease severity, review treatment failures, address treatment in a step wise fashion and cover the emerging science and implications for new therapies." The yardstick has practical recommendations for physicians about which medications are appropriate at which stage of diagnosis.

Itching is the hallmark of AD, and the cycle of itching and scratching makes the condition worse because it causes damage to the skin and often creates secondary infections, which can be serious. AD patients are at increased risk, not only for skin infections, but, according to a recent study, also for multi-organ and systemic infections. Patients with AD can present with a range of , from mild intermittent disease to severe difficult-to-control disease.

"All patients must keep their skin highly moisturized, regardless of the activity or severity of their disease" says allergist Luz Fonacier, MD, ACAAI board member and co-author of the yardstick. "We emphasize throughout the yardstick that even when patients step up to stronger medications, they should still continue basic treatment of bathing with warm water followed immediately with heavy moisturization, i.e. soak and seal."

The last few years have seen the introduction of targeted therapies, also known as "precision medicine". Two new medications have recently been approved for AD. The first, crisaborole, is an ointment that reduces itching, redness and swelling of the skin. It is the first anti-inflammatory to be approved for the treatment of mild to moderate AD in more than 15 years. It is approved for patients 2 years of age or older. Dupilumab, the second new medication, is a biologic therapy given by injection for 18 years or older with moderate to severe AD who haven't responded to, or can't use topical medications.

"There are effective medications available that help relieve AD symptoms and now can also target some of the underlying mechanisms of the disease," says Dr. Fonacier. "People with AD have been frustrated by the limitations of existing treatments. We're very excited by the new medications which were developed based on better understanding of . We expect additional therapies to be approved soon. Allergists have the right training and expertise to diagnose AD, and to offer relief with the right treatments. We're glad we can add these treatments to our arsenal of weapons to combat the symptoms of AD."

Explore further: New treatments help those with mild, moderate and severe eczema

Related Stories

New treatments help those with mild, moderate and severe eczema

October 27, 2017
If you think only infants suffer from eczema, think again. The uncomfortable, itchy rash that most people relate to babies and young children occurs frequently in adults. Although many adults with atopic dermatitis (commonly ...

Allergy sufferers are allergic to treatment more often than you'd think

November 6, 2014
Whether allergy sufferers have symptoms that are mild or severe, they really only want one thing: relief. So it's particularly distressing that the very medication they hope will ease symptoms can cause different, sometimes ...

Two meds not always better than one for seasonal allergic rhinitis

November 7, 2017
In a newly updated clinical practice guideline, published in Annals of Allergy, Asthma and Immunology, allergists offer practical advice on the best types and amounts of medications to treat seasonal allergic rhinitis. Annals ...

Clinicians need a clear definition of severe asthma for precise management

November 14, 2017
Those who treat patients suffering with severe asthma know how frustrating it can be to try to get the disease under control - despite the introduction in recent years of both biologics and bronchial thermoplasty. These treatments ...

FDA approves 1st drug for moderate and severe eczema cases

March 28, 2017
U.S. regulators have approved the first powerful, injected medicine to treat serious cases of the skin condition eczema.

Hay fever sufferers prefer prescription medication, but use over-the-counter relief

November 5, 2015
Anyone suffering with seasonal allergies knows the local pharmacy carries shelves full of over-the-counter medications to help manage symptoms. Unfortunately, most seasonal allergy sufferers take over-the counter (OTC) products ...

Recommended for you

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

New immunotherapy targeting blood-clotting protein

October 15, 2018
Normally, the blood protein fibrin does not enter the brain. But in several neurological disorders, the blood-brain barrier—which keeps large molecules in the blood from entering the brain—becomes abnormally permeable, ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Immune health maintained by meticulously ordered DNA

October 15, 2018
Walter and Eliza Hall Institute researchers have revealed how immune health is maintained by the exquisite organisation skills of a protein called Pax5.

Enzyme that triggers autoimmune responses from T-cells in patients with MS found

October 11, 2018
A team of researchers from Switzerland, the U.S. and Spain has isolated an enzyme that triggers an autoimmune response from T-cells in patients with MS. In their paper published in the journal Science Translational Medicine, ...

Scientists reveal new cystic fibrosis treatments work best in inflamed airways

October 11, 2018
A new UNC School of Medicine study shows that two cystic fibrosis (CF) drugs aimed at correcting the defected CFTR protein seem to be more effective when a patient's airway is inflamed. This is the first study to evaluate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.